Investors · CSE: PHRM · OTCQB: PHRRF
Building the specialty pharma company for medicines mass manufacturing was never built to make.
Exclusive North American CraftMake™ distribution, proprietary 503A launches targeted from Q4 2026, and a rare pediatric NDA targeted for Q4 2028.
The opportunity in front of us
1 · The target: large markets and a national network
US$295BPeptide therapeutics by 2033, up from US$141B
US$1.2TPersonalized medicine by 2033, up from US$567B
US$59BMedical countermeasures by 2030, up from US$41B
10,000+Potential preparedness nodes: commercial work in peacetime, countermeasures in an emergency
2 · The path: catalysts and what each unlocks
Q4 2026First 503A launches; CraftMake™ orders; designation applicationsProduct revenue begins
Q1 2027Ketamine dissolvable tablet launch; pre-IND meetingTelehealth sales; first ANDA payments expected
Next 12 monthsUp to 50 CraftMake™ placementsRecurring revenue and the first nodes
2027–28Licences, readiness contracts, new programsUltra-rare, psychedelic and discontinued medicines
Q4 2028Rare pediatric NDA (target)Path to approval and orphan exclusivity
BeyondFirst FDA-approved printed medicinePotential voucher; reported sales US$100–155M
3 · The moat: how the pieces lock together
Exclusive rightsSole North American CraftMake™ distributor
Installed printersEach earns repeat revenue and can become a node
Our formulations & dataPharmaTher owns its formulations, data and filings
Switching costsChanging systems means validating formulations again
A moat that widens with every placementMore recurring revenue, data and nodes
Non-dilutive upside: ketamine ANDA >US$25M potential · 49% of Sairiyo Therapeutics
Market sizes are third-party estimates of total markets, not PharmaTher revenue. Nodes require site qualification; readiness contracts are prospective. Voucher values are from 2024–25 sale press releases; award and value are not assured. Targets and timelines are internal estimates and forward-looking. Forward-looking statements